Global Centers for Therapeutic Innovation.
Davis helped to partner scientists from academic research centers around the world with Pfizer’s leading drug development teams in an effort to accelerate drug development initiatives. He also helped with Pfizer’s collaboration with Ensemble Discovery Corp. to discover, develop and commercialize novel compounds that are active against important therapeutic targets, particularly those involving protein-protein interactions.
Davis represented StemCells Inc. in its initial public offering and in more than 20 subsequent financings, as well as licensing and collaboration endeavors. He further represented numerous underwriters, including JPMorgan, Deutsche Bank and Goldman Sachs in initial public offerings and other public financings for biotech and medical device companies. This alone would be an asset to any biotech company, but now he joins the team that includes decades of proven experience who all aim to make GT Biopharma succeed as a leading biotech firm.
Outside of the impressive credentials that are being brought to GT Biopharma by Cross, Urbanski and Davis, Dr. Clarence-Smith has also helped add to GT Biopharma through the drug therapy pipeline that GT Biopharma currently holds. She served a vital role during the merger between Oxis International and Georgetown Translational Pharmaceuticals (now GT Biopharma). This further enhanced the company’s pipeline with entirely new and distinct drug therapies.
As the co-founder of Chase Pharmaceuticals, she served as the chairman of the company’s board for years (2008 to 2014) and through her time there, she helped build Chase into an organization that was eventually acquired by Allergan PLC in 2016. In all reality, the deal could be valued at nearly $900 million with milestones.
Dr. Clarence-Smith has come on board to captain the ship with GT Biopharma’s neurology division. Her track record of successes has been vast and her discoveries have led to several companies being acquired for their therapies.
As the head of CNS development at Sanofi, Hoffmann-La Roche and Otsuka, Dr. Clarence-Smith developed, secured approval for and supported the launches of significant neurological treatments. This includes Abilify® (aripiprazole), which is a $7 billion peak-year sales pharmaceutical drug used in the treatment of schizophrenia and bipolar disorder. Her expertise is now influencing GT Biopharma’s biopharma pipeline.
What other biotechnology company of this size do you know of that has the leadership of this caliber but with a market cap that’s under $100 million? It should also be mentioned that these industry veterans could most likely have their pick of the litter when it comes to choosing which companies they want to be part of. It stands to reason that the pipeline of therapies as well as future potential of GT Biopharma have created a unique situation that has attracted some of biotech’s best.
Don't take my word for it. Dig up your own DD!
